OneVentures

Following the success of our earlier equity funds - Fund I, Fund II and Fund V - we’re excited to launch our 1V Growth Fund VII! The fund will make investments of $10M to $30M in transformative tech companies that have demonstrated significant potential and need support accelerating their growth and expansion in global markets.  "Fund VII will continue our strategy of partnering closely with a concentrated portfolio of companies to provide operational and strategic guidance to propel them to the next level. We have a successful track record of investing in visionary founders who have used our expertise to grow their companies and have a global impact.” – Dr Michelle Deaker, Founding Partner & Managing Director    We are looking forward to continuing to build strong partnerships with founders and supporting Aussie businesses as they drive innovation and change.  Read about the launch, link in our comments 👇

Congratulations to DermR Health on winning the SXSW Sydney Pitch! Stefan Mazy, DermR Health CEO & founder, pitched a MedTech startup on a mission to prevent one billion skin biopsies by combining a non-invasive microneedle patch technology with genomics. The DermR patch can extract skin cells painlessly by collecting just a few cells to conduct pre-screenings, potentially eliminating the need for unnecessary biopsies. Our Founding Partner, Dr Michelle Deaker, had a great time as a Grand Finalist Judge alongside Melanie Silva (Google ANZ), Steven Maarbani (VentureCrowd) and Abheek Anand (Peak XV Partners) Good luck, DermR Health, pitching again at SXSW 2025 in Texas. A huge shoutout to all the finalists - Airee Felt, Outread, OVUM. Technology, SpaceDraft, The Laundry Lady, and WaveX: Wave Powered Generators

"The best time to raise capital is when you don't need it"   Our Investment Analyst, Shawn Li recently sat down with Pippin Barry from Dexterity Law to discuss growth credit, its role in supporting tech businesses and how it differs from traditional lenders.   🟠 The best time to raise growth credit is when your business has 9-12 months of runway, ensuring better terms and smoother negotiations.   🟠 Our investors look beyond algorithms, focusing on the company's team, traction and business model, to offer more tailored financing.    🟠 We offer more than capital by providing strategic guidance, connections to investors and operational support to fuel growth. Read the full interview 👉 https://lnkd.in/gxswCixn

"It's a long game and we play the long game at UniQuest for #UQ," says our CEO Dr Dean Moss GAICD RTTP about commercialising university research to solve the problems that affect us all. Check-out the video on The University of Queensland start-up Vaxxas and its revolutionary needle-free vaccine #tech, the high-density microarray patch (HD-MAP). Hear from Vaxxas CTO Angus Forster and Dr Moss on how this exciting Brisbane company, founded by us in 2011, is developing a potentially transformational global health tool. 🔬🧬👏🚫💉 #vaccine #researchcommercialisation #techtransfer #startup #globalhealth

We’re proud to see our Founding and Managing Partner, Dr Michelle Deaker alongside, Dr Daniel Timms, founder of BiVACOR and David Hoey, CEO of Vaxxas, named among The Australian's 2024 Top 100 Innovators! Congratulations to all the Innovators. Complete list here https://shorturl.at/d0aGV Michelle's recognition highlights her commitment to Australian innovation, which underpins OneVentures' strategy of investing in companies that solve real-world problems. It also celebrates her successful career at OneVentures and her prior achievements as a technology entrepreneur. Daniel Timms was recognised for founding BiVACOR’s Total Artificial Heart (TAH). ❤️ BiVACOR is a clinical-stage medical device company developing the TAH, the first long-term solution for patients with severe heart failure. ❤️ Designed for patients with end-stage heart failure, the TAH is designed to replace the native heart's function, to provide vital support while they await a transplant. TAH represents a paradigm shift in artificial heart design, using magnetic levitation technology and a single moving part it has the potential to revolutionise the heart failure field. ❤️ BiVACOR is conducting an FDA-approved Early Feasibility Study and have announced two successful in-human implants this year. David Hoey was recognised as president and CEO of Vaxxas. 💉🙅 Vaxxas is developing a needle-free vaccine technology, the high-density microarray patch (HD-MAP). 💉🙅 The Vaxxas patch consists of thousands of very short (0.25mm) vaccine-coated microprojections. When applied to the skin, via a small applicator, the patch efficiently delivers vaccine to the abundant immune cells in the skin's surface. 💉🙅 With 8 major vaccine programs in development and 3 moving into Phase II trials, this year Vaxxas launched their largest Phase I clinical trial, an avian influenza vaccine trial under their first US FDA IND (Investigational New Drug application)in a program supported by the US government department BARDA. Congratulations Dr Michelle Deaker, Daniel Timms and David Hoey – your groundbreaking work is an example of the power of Aussie innovation 👏

Exciting news - we're welcoming Bevin Shields to the OneVentures Partnership! With over 20 years of experience in growth equity, M&A and capital markets, Bevin has joined us to lead our growth equity investments, including our recently launched Fund VII, alongside Dr Michelle Deaker and Nigel Dews. Fund VII is targeting $200 million to support growth technology companies by providing capital and our operational support to boost sales, enhance marketing and drive expansion into new regions. "We're not just investors, we're also operators in terms of our approach and that is pretty unique. So, it's deliberate because at this growth phase, you have to that breadth of experience across a number of key areas" - Bevin Shields His extensive experience will be invaluable in driving success for our portfolio companies and investors. Great to have you on the team, Bevin alongside Nick Gainsley, Sarah Meibusch, Matt Sinnamon, Nigel Dews and Founding Partners Paul Kelly, Anne-Marie Birkill and Dr Michelle Deaker

We’re excited for SXSW Sydney 2024 next week! Here's where you can find us 👀 Our Founding Partner, Dr Michelle Deaker, will be a Grand Finalist Judge at SXSW Sydney Pitch, alongside Wesley Chan (FPV Ventures), Melanie Silva (Google ANZ) and Steven Maarbani (VentureCrowd). This year’s theme, ‘What’s Next’, showcases innovative, mission-driven startups from around the world, offering founders a chance to gain recognition, connect with investors and share solutions that could shape the future. 📅 Thursday, 17th October 🕕 3:30pm - 10pm Rhianna Miller is hosting a WinVC breakfast for women in venture capital in collaboration with VC Women Down Under 📅 Wednesday, 16th October 🕕 8:30am - 10am Register here 🎟️ https://lu.ma/xb4zmgiz 👀 see you there!

Exciting news from Buildkite! They’ve just announced the industry’s first Scale-Out Delivery Platform, combining multiple previous DevOps tools into a single integrated platform 🪁   This new platform simplifies the process for organisations by eliminating the need to install and configure additional tools separately, making it easier to adopt DevOps best practices. Software delivered using Buildkite is in use by more than 1 billion people daily through their customers such as Airbnb, Canva, Elastic, Lyft, PagerDuty, Pinterest, PlanetScale, Shopify, Slack, Tinder, Twilio, Uber and Wayfair. What’s included in the Scale-Out Delivery Platform?   🪁 Buildkite Pipelines: A scalable workflow orchestration engine for flexible, programmable software delivery automation. 🪁 Buildkite Test Engine: A unified platform for distributed, intelligent test execution with real-time insights. 🪁 Buildkite Package Registries: A high-performance asset management service offering rapid indexing and enhanced security. 🪁 Buildkite Mobile Delivery Cloud: A pre-configured cloud environment for mobile app delivery featuring performance-optimized build systems and per-minute pricing.   Congrats Keith Pitt and the Buildkite team on the launch! Click the link in the comments for more info 👇

We are incredibly proud of BiVACOR for completing their second in-human implantation of the Total Artificial Heart (TAH) as part of their FDA early feasibility study. A true demonstration of the power of Australian innovation. Congratulations to Daniel Timms, William Cohn and the BiVACOR team 👏

How do you tackle the challenges of scaling your business globally? Our Founding Partner and Managing Director, Dr Michelle Deaker, is joining Lauren Humphrey from Tandem and Nan Meka at NiceTo’s #StartupPaletteShow. They’ll discuss global scaling strategies and offer advice for founders, operators and investors. Michelle will share her insights on identifying and supporting high-potential startups, based on her experience guiding high-growth technology companies into international markets. Michelle will highlight the attributes that set apart the companies that go on to global success. 📅 Date: October 10th 🕠 Time: 5:30 - 8:30 pm Link in the comments to register   Investment NSW